PortfoliosLab logoPortfoliosLab logo
NWBO vs. GE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NWBO vs. GE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Northwest Biotherapeutics, Inc. (NWBO) and General Electric Company (GE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NWBO achieves a -28.31% return, which is significantly lower than GE's 17.21% return. Over the past 10 years, NWBO has underperformed GE with an annualized return of -9.39%, while GE has yielded a comparatively higher 10.46% annualized return.


NWBO

1D
-0.61%
1M
-11.45%
6M
-43.62%
YTD
-28.31%
1Y
-35.62%
3Y*
-32.04%
5Y*
-32.84%
10Y*
-9.39%
ALL TIME*
-30.38%

GE

1D
1.42%
1M
-4.50%
6M
17.68%
YTD
17.21%
1Y
34.35%
3Y*
59.40%
5Y*
41.70%
10Y*
10.46%
ALL TIME*
8.89%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$1.27B$1.39B$1.61B
$362.88K$599.45K$662.34K

NWBO vs. GE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NWBO
Northwest Biotherapeutics, Inc.
-28.31%-16.74%-60.81%-10.64%12.07%-54.10%626.19%2.19%-14.38%-31.05%
GE
General Electric Company
17.21%85.73%64.83%95.71%-10.92%9.69%-2.73%54.00%-55.39%-42.92%

Correlation

The correlation between NWBO and GE is -0.02, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

-0.02

Correlation (3Y)
Balances recent behavior with more history.

-0.01

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.03

Correlation (10Y)
Provides a long-term view across more market conditions.

0.03

Correlation (All Time)
Calculated using the full available price history since Dec 14, 2001

0.04

Fundamentals

Market Cap

NWBO:

$266.22M

GE:

$373.60B

EPS

NWBO:

-$0.06

GE:

$8.48

PS Ratio

NWBO:

261.15

GE:

7.52

Total Revenue (TTM)

NWBO:

$937.00K

GE:

$50.68B

Gross Profit (TTM)

NWBO:

$416.00K

GE:

$17.96B

EBITDA (TTM)

NWBO:

-$79.62M

GE:

$11.56B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NWBO vs. GE — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

NWBO
NWBO Risk / Return Rank: 2121
Overall Rank
NWBO Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
NWBO Sortino Ratio Rank: 2323
Sortino Ratio Rank
NWBO Omega Ratio Rank: 2323
Omega Ratio Rank
NWBO Calmar Ratio Rank: 2020
Calmar Ratio Rank
NWBO Martin Ratio Rank: 1616
Martin Ratio Rank

GE
GE Risk / Return Rank: 7474
Overall Rank
GE Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
GE Sortino Ratio Rank: 7171
Sortino Ratio Rank
GE Omega Ratio Rank: 7171
Omega Ratio Rank
GE Calmar Ratio Rank: 7575
Calmar Ratio Rank
GE Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

NWBO vs. GE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Northwest Biotherapeutics, Inc. (NWBO) and General Electric Company (GE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NWBOGEDifference
Sharpe ratioReturn per unit of total volatility

-1.54

Sortino ratioReturn per unit of downside risk

-1.98

Omega ratioGain probability vs. loss probability

0.95

1.20

-0.25

Calmar ratioReturn relative to maximum drawdown

-0.63

1.61

-2.25

Martin ratioReturn relative to average drawdown

-1.19

4.25

-5.44

NWBO vs. GE - Sharpe Ratio Comparison

The current NWBO Sharpe Ratio is -0.50, which is lower than the GE Sharpe Ratio of 1.05. The chart below compares the historical Sharpe Ratios of NWBO and GE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NWBO vs. GE - Drawdown Comparison

The maximum NWBO drawdown since its inception was -99.99%, which is greater than GE's maximum drawdown of -85.53%. Use the drawdown chart below to compare losses from any high point for NWBO and GE.


Loading charts...

Drawdown Indicators


NWBOGEDifference

Max Drawdown

Largest peak-to-trough decline

-99.99%

-85.53%

-14.46%

Max Drawdown (1Y)

Largest decline over 1 year

-52.03%

-20.85%

-31.18%

Max Drawdown (3Y)

Largest decline over 3 years

-85.24%

-21.36%

-63.88%

Max Drawdown (5Y)

Largest decline over 5 years

-91.96%

-44.94%

-47.02%

Max Drawdown (10Y)

Largest decline over 10 years

-93.33%

-80.94%

-12.39%

Current Drawdown

Current decline from peak

-99.99%

-4.91%

-95.08%

Average Drawdown

Average peak-to-trough decline

-97.16%

-25.74%

-71.42%

Ulcer Index

Depth and duration of drawdowns from previous peaks

27.64%

7.91%

+19.73%

Volatility

NWBO vs. GE - Volatility Comparison

Northwest Biotherapeutics, Inc. (NWBO) has a higher volatility of 17.38% compared to General Electric Company (GE) at 9.01%. This indicates that NWBO's price experiences larger fluctuations and is considered to be riskier than GE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NWBOGEDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.38%

9.01%

+8.37%

Volatility (6M)

Calculated over the trailing 6-month period

38.84%

25.88%

+12.96%

Volatility (1Y)

Calculated over the trailing 1-year period

66.37%

32.16%

+34.21%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

82.08%

30.96%

+51.12%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

92.64%

36.44%

+56.20%

Dividends

NWBO vs. GE - Dividend Comparison

NWBO has not paid dividends to shareholders, while GE's dividend yield for the trailing twelve months is around 0.46%.


PositionTTM20252024202320222021202020192018201720162015
GE
General Electric Company
0.46%0.47%0.67%0.25%0.38%0.34%0.37%4.12%4.89%4.81%2.94%2.95%
NWBO
Northwest Biotherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

NWBO vs. GE - Financials Comparison

This section allows you to compare key financial metrics between Northwest Biotherapeutics, Inc. and General Electric Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


NWBO and GE have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NWBO has higher volatility (17.38%) compared to GE (9.01%). In terms of maximum drawdown, NWBO dropped -99.99% vs GE's -85.53%.

GE currently has the higher Sharpe Ratio (1.05 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NWBO and GE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer